Reich, Kristian http://orcid.org/0000-0001-5248-4332
Armstrong, April W. http://orcid.org/0000-0003-0064-8707
Foley, Peter http://orcid.org/0000-0001-5891-5607
Song, Michael http://orcid.org/0000-0001-8177-9543
Miller, Megan http://orcid.org/0000-0002-8676-6706
Shen, Y. K. http://orcid.org/0000-0002-5870-5180
You, Yin http://orcid.org/0000-0001-7741-9270
Han, Chenglong http://orcid.org/0000-0001-7175-7834
Gordon, Kenneth B. http://orcid.org/0000-0002-9347-0292
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
https://doi.org/10.1007/s13555-023-01012-z
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
https://doi.org/10.1007/s40257-020-00555-7
Funding for this research was provided by:
Janssen Research and Development
Article History
First Online: 10 September 2020
Declarations
:
: This study was funded by Janssen Research & Development, LLC.
: K. Reich has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GlaxoSmithKline, Janssen, Janssen-Cilag, Kyowa Kirin, Leo Pharma, Medac, Merck Sharp & Dohme, Novartis, Miltenyi Biotec, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB, Valeant, and Xenoport. A.W. Armstrong has served as a research investigator and/or consultant to AbbVie, Janssen, Eli Lilly, Leo Pharma, Novartis, UCB, Ortho Dermatologics, Dermira, KHK, Sanofi, Regeneron, Sun Pharma, Bristol Myers Squibb, Dermavant, and Modernizing Medicine. P. Foley has served as an advisor and/or been a consultant for and/or received speaker’s bureau/honoraria and/or received research and/or travel grants from and/or participated in clinical trials (investigator) for the following companies: AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Boehringer Ingelheim, Botanix, Celgene, Celtaxsys, CSL, Cutanea, Dermira, Eli Lilly and Company, Galderma, Geneseq, Genetech, GlaxoSmithKline, Hexima, Janssen, Leo Pharma, Mayne Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Reistone, Roche, Sanofi, Sun Pharma, UCB Pharma, Valeant, and Wintermute. K.B. Gordon has received research/grant support from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma, and honoraria for consultation from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, Novartis, and UCB Pharma. M. Song, M. Miller, Y.K. Shen, and Y. You are employees of Janssen Research & Development, LLC, and C. Han is an employee of Janssen Global Services, LLC, and all own stock in Johnson & Johnson, of which Janssen is a subsidiary.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: All participants provided written informed consent prior to any study-related procedures.
: All participants provided written informed consent prior to any study-related procedures.
: Patients signed informed consent regarding publishing their data.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at ExternalRef removed. Datasets related to this article will be available by request or at ExternalRef removed (NCT02207244) when the study concludes.
: Not applicable.